April 27, 2017 by Chuck Huber
Blueprint Bio and Emerald Logic MERGE to Create Healthcare Innovation Company liquid biosciences, inc.
– New Entity Will Advance Precision Medicine through Actionable Insights –
Aliso Viejo, CA – August 15, 2017 – BluePrint Bio and Emerald Logic, providers of innovative diagnostics and analytics used to inform precision medicine, today announced the merger of the two companies to create one private entity, Liquid BioSciences, Inc. The new company will combine a highly scientific biomarker research model with sophisticated predictive health algorithms into one solution with the potential to transform clinical decisions and patient outcomes. Dennis Kogod has been appointed chairman and chief executive officer of Liquid BioSciences, joining the organization from DaVita HealthCare Partners International, where he served as chief executive officer.
“Precision medicine has the potential to change the current one-size-fits-all approach in healthcare and personalize treatments to produce game-changing improvements in patient outcomes,” said Dennis Kogod, Liquid Biosciences’ chairman and chief executive officer. “The merger of Blueprint Bio and Emerald Logic brings together a seasoned leadership team with extensive expertise in healthcare analytics and biomarker identification, as well as a shared mission to advance the rapidly evolving science of precision medicine.”
Liquid BioSciences combines the use of a comprehensive multi-omics platform with a novel bio-inspired signal processing analytic technology to provide a powerful solution to extremely complex data sets. The company’s platform has been tested on over 100 validation projects and Liquid BioSciences’ intellectual property comprises 115+ trade secrets and patents in the areas of biomarker discoveries, core bio-analytics technology and market-responsive solutions.
“Liquid Biosciences has the potential to transform the way we make clinical decisions by allowing us to perform a comprehensive evaluation of a set of individual patient information,” said Barry Straube, M.D., Former Chief Medical Officer for the Centers for Medicare and Medicaid Services (CMS). “As a result, we will better predict individual patient responses to available therapies and enable early personalized interventions to improve clinical outcomes while avoiding unnecessary costs.”
Healthcare providers, managed care organizations and clinical investigators can utilize Liquid BioSciences’ technology to predict clinical outcomes for clinical trial screening and recruitment, create individualized interventions for patients and further their understanding of the mechanisms of disease and disease progression. This approach has the potential to allow for more targeted pathways to drive better clinical decisions and patient outcomes, despite how complex treatment decisions can be.
“The human body is a highly-complex and non-linear system, which makes it challenging to accurately model and predict patient outcomes even with state-of-the art machine learning methods. Liquid’s platform, however, can concurrently analyze many thousands to millions of variables per patient and produce highly-accurate, human-readable models,” said Dr. Michael B. Yaffe, Professor of Biology and Biological Engineering at the Massachusetts Institute of Technology.
In addition to the appointment of Mr. Kogod, Liquid BioSciences has engaged critical staff members from the two original organizations, including Patrick Lilley, CEO and founder of Emerald Logic, and Matthew Nunez, CEO and founder of BluePrint Bio. The management team of Liquid BioSciences will include:
Visit the Liquid BioSciences’ website for additional information at www.liquidbiosciences.com.
About Liquid BioSciences, Inc.
Liquid BioSciences is a healthcare innovation company that enables the precise delivery of clinical care by removing guesswork, variable diagnoses and treatment strategies based on one-size-fits-all medicine. Liquid BioSciences leverages data from direct and indirect sources to provide a more comprehensive view of an individual patient. The company uses its proprietary mathematics and multi-omics assay technology to predict clinical outcomes and enable early intervention to mitigate expensive downstream consequences. Additional information about Liquid BioSciences can be found here.
Media Contacts:
Pooja Goel
Liquid BioSciences
Chief Commercial Officer
310-970-2513
Edie DeVine
GCI Health on behalf of Liquid BioSciences